Please ensure Javascript is enabled for purposes of website accessibility

While Big Pharma Tanked, Gilead Sciences and Regeneron Soared

By Cory Renauer – Apr 25, 2020 at 6:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The global economic slowdown hammered many of their peers, but swift decision-making has helped lift these two biotechs' shares much higher.

Investors watched in horror as shares of the world's largest biopharmaceutical companies tumbled during the first quarter of 2020. However, thanks to some swift action when the novel coronavirus was still just a blip on the radar, Regeneron (REGN -1.93%) and Gilead Sciences (GILD -1.34%) did more than avoid the COVID-19 carnage -- their stock prices soared.

Invaluable planning 

In mid-March, The iShares U.S. Pharmaceuticals ETF was down more than 25% from where it started 2020 and it's still down 5.9% on the year.  But investors flocked to Regeneron and Gilead because it was clear they had already started digging tunnels through the mess that lay ahead.

Coronavirus test tube sample

Image source: Getty Images.

On March 17, Regeneron announced efforts to develop a combination of antibodies for the treatment of COVID-19 or to prevent its transmission altogether, and the biotech's recent track record is impressive. The FDA recently accepted an application to treat the Ebola virus with REGN-EB3, an antibody cocktail that showed strong evidence of efficacy in a head-to-head study with other experimental Ebola treatments.

Will their plans come together?

Gilead Sciences' stock soared because it had a broad-spectrum antiviral candidate called remdesivir ready to put into human trials against SARS-CoV-2 while all of its peers, Regeneron included, were still selecting candidates to begin pre-clinical testing. Before getting too excited, though, it's worth remembering that remdesivir was tested against Ebola in the same clinical trial as REGN-EB3, and Gilead's drug produced fairly disappointing results. 

An early peek at data from a controlled clinical trial that was halted before it could be completed suggests remdesivir didn't improve outcomes for COVID-19 patients. Gilead was quick to point out flaws in the unpublished paper. By contrast, healthcare industry news website STAT last week reported that the section of Gilead's ongoing remdesivir trial being conducted at University of Chicago Medicine had seen very promising results

Given the conflicting studies, it's likely too soon to come to any conclusions about the experimental antiviral drug.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$691.82 (-1.93%) $-13.60
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.07 (-1.34%) $0.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.